* 2009 operating margin rises to 17.4 percent
* Maintains 2010 target of 17-18 percent
* Aims for 18-20 percent by 2015 (Adds 2015 target)
PARIS, March 8 (Reuters) - French pharmaceutical groups BioMerieux and ExonHit said on Monday they were ending their collaboration on colon cancer, but would continue to work together on prostate cancer.
BioMerieux said its 2009 operating income rose 9.5 percent to 204 million euros ($277.1 million), on sales that increased 10.2 percent to 1.223 billion euros.
It said it aimed for 2010 sales growth of some 7 percent and an operating margin of 17-18 percent, against 17.4 percent for 2009.
For 2015, it aims for annual sales growth of 7-9 percent and an operating margin of 18-20 percent.
(Reporting by Marcel Michelson)